Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Launched by ASTELLAS PHARMA INC · May 30, 2019
Trial Information
Current as of August 02, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the safety and effectiveness of a medication called peficitinib for patients with rheumatoid arthritis (RA). The goal is to understand how well this treatment works in real-life situations for people who are starting peficitinib for the first time. The trial is currently recruiting patients of all ages and genders who have RA and are beginning their treatment with this drug.
If you or a family member have rheumatoid arthritis and are considering peficitinib, you might be eligible to participate in this study. As a participant, you can expect to be monitored for how well the medication works and any side effects it may cause. Since there are no specific exclusions for this trial, it opens the door for many patients with RA to contribute to important research that could benefit others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients with rheumatoid arthritis (RA) treated with peficitinib for the first time.
- Exclusion Criteria:
- • Not applicable.
About Astellas Pharma Inc
Astellas Pharma Inc. is a global pharmaceutical company dedicated to improving the health of patients through innovative research and development. With a strong focus on urology, oncology, immunology, and neuroscience, Astellas is committed to advancing medical science and delivering transformative therapies. The company operates with a patient-centric approach, striving to address unmet medical needs while adhering to the highest standards of ethics and compliance in clinical trials. Astellas leverages cutting-edge technology and collaborates with healthcare professionals and institutions worldwide to bring forward new treatment options that enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fukuoka, , Japan
Hokkaido, , Japan
Tokushima, , Japan
Tokyo, , Japan
Hyogo, , Japan
Kanagawa, , Japan
Ibaraki, , Japan
Aichi, , Japan
Kyoto, , Japan
Hiroshima, , Japan
Nagano, , Japan
Akita, , Japan
Aomori, , Japan
Chiba, , Japan
Ehime, , Japan
Fukui, , Japan
Fukushima, , Japan
Gifu, , Japan
Gunma, , Japan
Ishikawa, , Japan
Iwate, , Japan
Kagawa, , Japan
Kagoshima, , Japan
Kochi, , Japan
Kumamoto, , Japan
Mie, , Japan
Miyagi, , Japan
Miyazaki, , Japan
Nagasaki, , Japan
Nara, , Japan
Niigata, , Japan
Oita, , Japan
Okayama, , Japan
Okinawa, , Japan
Osaka, , Japan
Saga, , Japan
Saitama, , Japan
Shiga, , Japan
Shimane, , Japan
Shizuoka, , Japan
Tochigi, , Japan
Tottori, , Japan
Toyama, , Japan
Wakayama, , Japan
Yamagata, , Japan
Yamaguchi, , Japan
Yamanashi, , Japan
Patients applied
Trial Officials
Central Contact
Study Director
Astellas Pharma Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials